1. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Issue 2 (February 2018) Authors: Amaria, Rodabe N; Prieto, Peter A; Tetzlaff, Michael T; Reuben, Alexandre; Andrews, Miles C; Ross, Merrick I; Glitza, Isabella C; Cormier, Janice; Hwu, Wen-Jen; Tawbi, Hussein A; Patel, Sapna P; Lee, Jeffrey E; Gershenwald, Jeffrey E; Spencer, Christine N; Gopalakrishnan, Vancheswaran; Bassett, R... Journal: Lancet oncology Issue: Volume 19:Issue 2(2018) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗